Core Viewpoint - The Hong Kong Innovative Drug ETF (513120) experienced a decline of 3.40% on October 13, with a trading volume of 5.241 billion yuan, indicating market volatility in the innovative drug sector [1] Group 1: Fund Performance - The fund's total shares increased by 259 million, bringing the latest total to 16.471 billion shares, with a significant increase of 2.650 billion shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 23.421 billion yuan [1] - Since its inception on July 1, 2022, the fund has achieved a return of 42.19%, while the return over the past month has been -7.00% [1] Group 2: Benchmark and Management - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the CSI Hong Kong Innovative Drug Index (denominated in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie serving as the fund manager [1]
10月13日港股创新药ETF（513120）份额增加2.59亿份
Xin Lang Cai Jing·2025-10-14 01:08